

# Wolfgang F Richter

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6269088/publications.pdf>

Version: 2024-02-01

31  
papers

1,811  
citations

430754

18  
h-index

377752

34  
g-index

36  
all docs

36  
docs citations

36  
times ranked

2337  
citing authors

#	ARTICLE	IF	CITATIONS
1	Gantenerumab: A Novel Human Anti-A $\beta$ Antibody Demonstrates Sustained Cerebral Amyloid- $\beta$ Binding and Elicits Cell-Mediated Removal of Human Amyloid- $\beta$ . <i>Journal of Alzheimer's Disease</i> , 2012, 28, 49-69.	1.2	335
2	Mechanistic Determinants of Biotherapeutics Absorption Following SC Administration. <i>AAPS Journal</i> , 2012, 14, 559-570.	2.2	253
3	Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities. <i>BioDrugs</i> , 2018, 32, 425-440.	2.2	237
4	Subcutaneous Absorption of Biotherapeutics: Knowns and Unknowns. <i>Drug Metabolism and Disposition</i> , 2014, 42, 1881-1889.	1.7	173
5	CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies. <i>Clinical Cancer Research</i> , 2018, 24, 4785-4797.	3.2	146
6	Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration. <i>MAbs</i> , 2012, 4, 243-255.	2.6	109
7	Analysis of erlotinib and its metabolites in rat tissue sections by MALDI quadrupole time-of-flight mass spectrometry. <i>Journal of Mass Spectrometry</i> , 2007, 42, 900-909.	0.7	105
8	Heparin chromatography as an <i>in vitro</i> predictor for antibody clearance rate through pinocytosis. <i>MAbs</i> , 2020, 12, 1683432.	2.6	44
9	Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody. <i>Nature Communications</i> , 2020, 11, 3196.	5.8	43
10	Tissue Distribution of a Therapeutic Monoclonal Antibody Determined by Large Pore Microdialysis. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2853-2859.	1.6	36
11	Interspecies Scaling of Interferon Disposition and Comparison of Allometric Scaling with Concentration-Time Transformations. <i>Journal of Pharmaceutical Sciences</i> , 1995, 84, 1285-1290.	1.6	34
12	Subcutaneous versus Intravenous Administration of Rituximab: Pharmacokinetics, CD20 Target Coverage and B-Cell Depletion in Cynomolgus Monkeys. <i>PLoS ONE</i> , 2013, 8, e80533.	1.1	31
13	Are Biotransformation Studies of Therapeutic Proteins Needed? Scientific Considerations and Technical Challenges. <i>Drug Metabolism and Disposition</i> , 2019, 47, 1443-1456.	1.7	30
14	6-Alkoxy-5-aryl-3-pyridinecarboxamides, a New Series of Bioavailable Cannabinoid Receptor Type 1 (CB1) Antagonists Including Peripherally Selective Compounds. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 9874-9896.	2.9	27
15	Hematopoietic cells as site of first-pass catabolism after subcutaneous dosing and contributors to systemic clearance of a monoclonal antibody in mice. <i>MAbs</i> , 2018, 10, 803-813.	2.6	26
16	In Vivo Biotransformation of the Fusion Protein Tetranectin-Apolipoprotein A1 Analyzed by Ligand-Binding Mass Spectrometry Combined with Quantitation by ELISA. <i>Analytical Chemistry</i> , 2016, 88, 11670-11677.	3.2	20
17	Animal Pharmacokinetics and Interspecies Scaling of Ro 25-6833 and Related (Lactamylvinyl)cephalosporins. <i>Journal of Pharmaceutical Sciences</i> , 1998, 87, 496-500.	1.6	19
18	The distribution pattern of radioactivity across different tissues in quantitative whole-body autoradiography (QWBA) studies. <i>European Journal of Pharmaceutical Sciences</i> , 2006, 28, 155-165.	1.9	18

#	ARTICLE	IF	CITATIONS
19	Subcutaneous Site-of-Absorption Study with the Monoclonal Antibody Tocilizumab in Minipigs: Administration Behind Ear Translates Best to Humans. <i>AAPS Journal</i> , 2020, 22, 63.	2.2	10
20	Immunogenicity, Inflammation, and Lipid Accumulation in Cynomolgus Monkeys Infused with a Lipidated Tetranectin-ApoA-I Fusion Protein. <i>Toxicological Sciences</i> , 2016, 150, 378-389.	1.4	8
21	Novel in Vivo and in Vitro Pharmacokinetic/Pharmacodynamic-Based Human Starting Dose Selection for Glofitamab. <i>Journal of Pharmaceutical Sciences</i> , 2022, 111, 1208-1218.	1.6	8
22	The Effects of Interleukin-6 Signal Blockade on Immune System, Reproductive and Skeletal Development in Juvenile Mice. <i>Birth Defects Research Part B: Developmental and Reproductive Toxicology</i> , 2013, 98, 170-182.	1.4	7
23	Reproductive and developmental toxicology studies with gantenerumab in PS2APP transgenic mice. <i>Reproductive Toxicology</i> , 2017, 73, 362-371.	1.3	7
24	High-Throughput, Sensitive LC-MS Quantification of Biotherapeutics and Biomarkers Using Antibody-Free, Peptide-Level, Multiple-Mechanism Enrichment via Strategic Regulation of pH and Ionic and Solvent Strengths. <i>Analytical Chemistry</i> , 2019, 91, 3475-3483.	3.2	7
25	Protein engineering of a stable and potent anti-inflammatory IL-37-Fc fusion with enhanced therapeutic potential. <i>Cell Chemical Biology</i> , 2022, 29, 586-596.e4.	2.5	7
26	Design of Experiment (DOE) Methods Maximize Information from a Minimal Number of Animals in Special Cases of Preclinical Bioavailability Testing. <i>Pharmaceutical Development and Technology</i> , 2003, 8, 453-458.	1.1	6
27	Neonatal Immune Tolerance Induction to Allow Long-Term Studies With an Immunogenic Therapeutic Monoclonal Antibody in Mice. <i>AAPS Journal</i> , 2016, 18, 354-361.	2.2	5
28	Challenges of non-clinical safety testing for biologics: A Report of the 9th BioSafe European Annual General Membership Meeting. <i>MABs</i> , 2021, 13, 1938796.	2.6	4
29	Potential errors in the volume of distribution estimation of therapeutic proteins composed of differently cleared components. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2011, 38, 581-593.	0.8	3
30	Nonclinical Development of Biologics: Integrating Safety, Pharmacokinetics, and Pharmacodynamics to Create Smarter and More Flexible Nonclinical Safety Programs Optimizing Animal Use. <i>International Journal of Toxicology</i> , 2021, 40, 270-284.	0.6	3
31	Impact of charge patches on tumor disposition and biodistribution of therapeutic antibodies. <i>AAPS Open</i> , 2022, 8, .	0.4	3